Ligand Pharmaceuticals (LGND) Other Non-Current Assets (2010 - 2026)

Ligand Pharmaceuticals has disclosed Other Non-Current Assets across 17 years of filings, most recently posting $13.0 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $13.0 million, up 64.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.0 million (up 64.56% YoY), and the FY2025 annual result was $12.6 million, down 60.35% from the prior year.
• Other Non-Current Assets came in at $13.0 million for Q1 2026 at Ligand Pharmaceuticals, up from $12.6 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $31.7 million in Q4 2024 to a low of $1.7 million in Q4 2022.
• The 5-year median for Other Non-Current Assets is $7.9 million (2025), against an average of $9.0 million.
• Across the five-year window, Other Non-Current Assets plunged 99.36% in 2022 and surged 396.4% in 2024, its largest moves.
• Ligand Pharmaceuticals' Other Non-Current Assets stood at $1.7 million in 2022, then surged by 268.2% to $6.4 million in 2023, then surged by 396.4% to $31.7 million in 2024, then slumped by 60.35% to $12.6 million in 2025, then climbed by 3.22% to $13.0 million in 2026.
• The last three Other Non-Current Assets figures came in at $13.0 million (Q1 2026), $12.6 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.